AUTHENTICATED
U.S. GOVERNMENT
INFORMATION
GPO

II

106TH CONGRESS
2D SESSION

S. 2015

To amend the Public Health Service Act to provide for research with respect to human embryonic stem cells.

IN THE SENATE OF THE UNITED STATES

JANUARY 31, 2000

Mr. SPECTER (for himself and Mr. HARKIN) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

---

A BILL

To amend the Public Health Service Act to provide for research with respect to human embryonic stem cells.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the ''Stem Cell Research Act of 2000''.

SEC. 2. RESEARCH ON HUMAN EMBRYONIC STEM CELLS.

Part G of the Title IV of the Public Health Service Act (42 U.S.C. 288 et seq.) is amended by inserting after section 498B the following:

"SEC. 498C. RESEARCH ON HUMAN EMBRYONIC STEM CELLS.

''(a) IN GENERAL.—Notwithstanding any other provision of law, the Secretary may only conduct, support, or fund research on, or utilizing, human embryos for the purpose of generating embryonic stem cells in accordance with this section.

''(b) SOURCES OF EMBRYONIC CELLS.—For purposes of carrying out research under paragraph (1), the human embryonic stem cells involved shall be derived only from embryos that otherwise would be discarded that have been donated from in-vitro fertilization clinics with the written informed consent of the progenitors.

''(c) RESTRICTIONS.—

''(1) IN GENERAL.—The following restriction shall apply with respect to human embryonic stem cell research conducted or supported under subsection (a):

''(A) The research involved shall not result in the creation of human embryos.

''(B) The research involved shall not result in the reproductive cloning of a human being.

''(2) PROHIBITION.—

''(A) IN GENERAL.—It shall be unlawful for any person receiving Federal funds to knowingly acquire, receive, or otherwise transfer any

human gametes or human embryos for valuable consideration if the acquisition, receipt, or transfer affects interstate commerce.

''(B) DEFINITION.—In subparagraph (A), the term 'valuable consideration' does not include reasonable payments associated with transportation, transplantation, processing, preservation, quality control, or storage.

''(d) GUIDELINES.—

''(1) IN GENERAL.—The Secretary, in conjunction with the Director of the National Institutes of Health, shall issue guidelines governing human embryonic stem cell research under this section, including the definitions and terms used for purposes of such research.

''(2) REQUIREMENTS.—The guidelines issued under paragraph (1) shall ensure that—

''(A) all Federal research protocols and consent forms involving human embryonic stem cell research must be reviewed and approved by an institutional review board; and

''(B) the institutional review board is empowered to make a determination as to whether or not the proposed research is in accordance with National Institutes of Health Guidelines

for Research Involving Human Pluripotent Stem Cells.

''(e) REPORTING REQUIREMENTS..—Not later than January 1, 2001, and each January 1 thereafter, the Secretary shall prepare and submit to the appropriate committees of Congress a report describing the activities carried out under this section during the preceding fiscal year, and including a description of whether and to what extent research under subsection (a) has been conducted in accordance with this section.''.

○